ASM 024

Drug Profile

ASM 024

Alternative Names: ASM-024

Latest Information Update: 05 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asmacure
  • Developer Odan Laboratories
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Muscarinic receptor modulators; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Aug 2015 Odan Laboratories acquires Asmacure Ltee
  • 10 Aug 2015 Phase-II development is ongoing for ASM 024 as a dry powder for inhalation for Asthma and chronic obstructive pulmonary disease
  • 08 Feb 2015 Asmacure terminates a phase I/II trial in Asthma in Canada (Inhalation, powder) (NCT01793298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top